Select Page

Nanodrugs process development

We develop GMP-ready processes and formulate nanodrugs for seamless transfer to GMP production.

GTP Bioways CDMO - Antibody drug conjugate development

A team of experts dedicated to the development of your nanoformulation

At GTP Bioways, we are aware of the hurdles that are intrinsic to the manufacturing of nanodrugs. For that reason, we will focus on mitigating the technology transfer issues from the early stages of development.

To best meet this challenge, GTP Bioways has developed a strong collaboration with CEA Tech, who has recognised expertise in nanovectorisation. Together, GTP Bioways and CEA Tech have built a pilot lab, that mirrors our GMP manufacturing facilities. This pilot lab is hosted by the CEA Toulouse office.

Our strong partnership with CEA Tech

CEA Tech infrastructure, skills and equipment are geared towards the development of mature technologies for molecule vectorisation for different therapeutic applications – including cancer diagnostic, vaccine applications and gene therapy.

Cell line Development process

A tailored approach to nanovectorisation

At GTP Bioways, we believe that one nanovectorisation technique does not apply to all API. To successfully vectorise a wide range of molecules, we work with our partner CEA Tech, who has recognised expertise in nanovectorisation.

The scientific team at CEA Tech will develop a formulation based on your project constraints and drawing on their expertise in nanoformulations such as lipid nanoparticles (LNPs) – including CEA’s proprietary technology, Lipidots® – liposomes, nanocrystals, etc.

To support our development and perform full characterisation of the product, CEA Tech scientific team will develop suitable methods using state-of-the-art analytical techniques. For very specific techniques not available in-house, we work with a panel of specialised partners.

Non-GMP manufacturing for pre-clinical development of nanodrugs

At GTP Bioways, we know that your main goal is to bring your candidate to the clinic as fast as possible. To do so, during feasibility, CEA Tech team will develop or optimise process of wide range of formula in which dispersion, emulsion, solution, or suspension producing small batches of a few mL at lab scale (GLP-like) for in vitro and in vivo studies.

Alongside nanoformulation feasibility studies, we can also conduct stability studies to ensure the long-term integrity of the formula as well as fulfilling clinical regulatory aspects. Our scientists, in partnership with CEA Tech, have comprehensive knowledge of what makes a robust method and they strive to generate meaningful, accurate data to support your target product profile.

And when you are ready for clinical trial, we have the infrastructure, the equipment and quality system to move your product through to clinic.

GTP Bioways CDMO - Bioconjugates Analytical Development

Discover more about GTP Bioways services


GMP Manufacturing


Analytical development


Fill & Finish

White paper

A Guide to Smooth CDMO Tech Transfer

The key parameters to be considered while choosing your next CDMO, as well as our tips to assess those parameters, and more!